Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 1
2011 1
2012 2
2013 2
2016 1
2017 1
2018 3
2019 2
2020 12
2021 9
2022 8
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S. Abu-Rustum N, et al. Among authors: wethington sl. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006. J Natl Compr Canc Netw. 2023. PMID: 36791750
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F. Wethington SL, et al. Clin Cancer Res. 2023 Aug 1;29(15):2800-2807. doi: 10.1158/1078-0432.CCR-22-2444. Clin Cancer Res. 2023. PMID: 37097611
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F. Shah PD, et al. Among authors: wethington sl. Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5. Gynecol Oncol. 2021. PMID: 34620496 Free PMC article. Clinical Trial.
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R II, Glaser S, Holmes J, Howitt BE, Kendra K, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian N, Espinosa S. Abu-Rustum NR, et al. Among authors: wethington sl. J Natl Compr Canc Netw. 2024 Mar;22(2):117-135. doi: 10.6004/jnccn.2024.0013. J Natl Compr Canc Netw. 2024. PMID: 38503056
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. Abu-Rustum NR, et al. Among authors: wethington sl. J Natl Compr Canc Netw. 2021 Aug 1;19(8):888-895. doi: 10.6004/jnccn.2021.0038. J Natl Compr Canc Netw. 2021. PMID: 34416706
48 results